Peter Attia· MD
by itself you know really lacks the specificity to be a high yield tool and so in in many cases actually as you probably know the PSA is being abandoned
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
by itself you know really lacks the specificity to be a high yield tool and so in in many cases actually as you probably know the PSA is being abandoned
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and really the only example is um PSA and again the false positive rates there um are so high that its benefit to harm has has you know been questioned many times and and that's why it's no longer you know um you know doesn't have a uspstf um grade A or B anymore